This report provides a high-level summary of the key outcomes and gaps based on the
research presented at the 2019 Viral Clearance Symposium and identifies new areas for …

This article introduces the white paper from the 2017 Viral Clearance Symposium. The 5th
Viral Clearance Symposium in Penzberg, Germany, addressed regulatory perspectives …

Session 5 of the 2023 Viral Clearance Symposium reviewed the strategy and process
understanding of viral clearance testing. Topics included learnings from the past, leveraging …

Session 7 of the 2023 Viral Clearance Symposium reviewed progresses in virus retentive
filtrations applied to both upstream and downstream processing. Upstream topics included …

This article describes a summary of discussions and outcomes from the 2019 Viral
Clearance Symposium Session 4 on the utilization of knowledge, both from within and …

The manufacturing processes of biological medicinal products are expected to be capable of
removing and/or inactivating viruses, to primarily provide for adequate safety margins to …

Viral inactivation has been demonstrated to be an effective viral clearance step in the
biologics purification processes. In the 2019 Viral Clearance Symposium, the topics were …

Successful implementation of continuous processing requires an understanding of how to
incorporate viral testing and clearance/inactivation into the process via representative small …

Viral clearance studies are mandated prior to entering clinical trials and for commercial
launch of biopharmaceuticals. These studies are a key component of risk mitigation to …

To ensure successful scale-up of continuous processing to large-scale production, it is
necessary to seamlessly incorporate viral testing and clearance/inactivation into …